Pfizer und BioNTech
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
August 23, 2022 06:45 ET | BioNTech SE
Daten einer weiterführenden Analyse mit 34 Fällen, die mindestens sieben Tage nach Verabreichung der primären Impfserie bestehend aus drei Dosen auftraten, zeigen eine Impfstoffwirksamkeit von 73,2 %...
Pfizer and BioNTech
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022 06:45 ET | BioNTech SE
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 yearsThe vaccine efficacy remained...
Pfizer und BioNTech
Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
August 22, 2022 10:30 ET | BioNTech SE
Die Daten stützen Antrag auf Notfallzulassung einer 30-µg-Auffrischungsdosis eines an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoffs für Personen ab 12 JahrenDie Unternehmen haben die...
Pfizer and BioNTech
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022 10:30 ET | BioNTech SE
Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and olderCompanies have rapidly...
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
August 22, 2022 01:05 ET | Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...
Dyadic Logo Current.jpg
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
August 10, 2022 16:00 ET | Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
iHealth Donates 1-Million A-Home Tests to the State of California
July 25, 2022 08:12 ET | iHealth Labs Inc
SAN JOSE, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- iHealth Labs, Inc., one of the major suppliers of at-home COVID tests in the U.S. market, is donating 1 million at-home COVID tests to the State...
Achiko Logo cropped.jpg
Achiko AG – Investor Briefing
July 07, 2022 15:22 ET | Achiko AG
ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a...
Dyadic Logo Current.jpg
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
July 05, 2022 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Pfizer und BioNTech
Pfizer und BioNTech schließen neue Liefervereinbarung mit der US-Regierung für zusätzliche Dosen des COVID-19-Impfstoffs
June 29, 2022 16:45 ET | BioNTech SE
Liefervereinbarung umfasst 105 Millionen 30 µg-, 10 µg- sowie 3 µg-Dosen, die bis einschließlich des vierten Quartals 2022 geliefert werden sollen; die US-Regierung hat die Option, 195 Millionen...